| Molly Marr-york, SLP | |
|
16500 Ventura Blvd Ste 414, Encino, CA 91436-5050 | |
| (818) 788-1003 | |
| (818) 788-1135 |
| Full Name | Molly Marr-york |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 16500 Ventura Blvd Ste 414, Encino, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013260546 | NPI | - | NPPES |
| SP 2673 | Other | CA | SLP, AUDIOLOGY AND HEARING AID DISPENSERS BOARD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP 2673 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Molly Marr-york, SLP 4420 Carpenter Ave, Studio City, CA 91607-4111 Ph: (818) 788-1003 | Molly Marr-york, SLP 16500 Ventura Blvd Ste 414, Encino, CA 91436-5050 Ph: (818) 788-1003 |
News Archive
Atritech, Inc. today announced initial enrollment into its confirmatory study, PREVAIL, comparing the WATCHMAN® Left Atrial Appendage Closure Device to long term warfarin therapy in patients with atrial fibrillation. Doctors at Central Baptist Hospital in Lexington, Kentucky enrolled the first patient.
Sangamo BioSciences, Inc. announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation.
Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.
EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has granted the Japanese development and commercialization rights to its oncology therapy Erwinase(R) to Ohara Pharmaceutical Company Limited. The agreement represents the first product partnership EUSA has established in Japan.
› Verified 8 days ago
Mrs. Jamie Diana Frost, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16500 Ventura Blvd, Encino, CA 91436 Phone: 818-788-1003 | |
Shelby Purmort, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16055 Ventura Blvd, Encino, CA 91436 Phone: 818-835-1868 | |
Sara Kubota, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16500 Ventura Blvd Ste 414, Encino, CA 91436 Phone: 818-788-1003 | |
Aiyana Smith, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16500 Ventura Blvd Ste 414, Encino, CA 91436 Phone: 818-788-1003 | |
Miss Vicki Chia Hui Lin, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 5292 Newcastle Ave Apt 4, Encino, CA 91316 Phone: 310-985-9866 | |
Zahid Khan, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 16500 Ventura Blvd Ste 414, Encino, CA 91436 Phone: 818-788-1003 Fax: 818-788-1135 |